Tumours and tremors: how PTEN regulation underlies both
Authors:
Open Access
- 21 February 2006
- journal article
- review article
- Published by Springer Nature in British Journal of Cancer
- Vol. 94 (5) , 620-624
Abstract
Mutations of the tumour suppressor PTEN (phosphatase and tensin homolog deleted on chromosome 10) are seen in many human cancers. However, dysregulation of PTEN may be involved in other disease states such as Parkinson's disease. This minireview describes recent work examining PTEN regulation and its implications for the development of both cancer and neurodegenerative disease.Keywords
This publication has 30 references indexed in Scilit:
- PTEN function: how normal cells control it and tumour cells lose itBiochemical Journal, 2004
- The Biology and Clinical Relevance of the PTEN Tumor Suppressor PathwayJournal of Clinical Oncology, 2004
- Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's diseaseAnnals of Neurology, 2004
- Regulation of Cell Migration by the C2 Domain of the Tumor Suppressor PTENScience, 2004
- Proteomic profiling drug-induced apoptosis in non-small cell lung carcinoma: identification of RS/DJ-1 and RhoGDIalpha.2003
- Regulation of constitutive expression of mouse PTEN by the 5′-untranslated regionOncogene, 2003
- PTEN: One Gene, Many SyndromesHuman Mutation, 2003
- Physiological Functions of Pten in Mouse Tissues.Cell Structure and Function, 2003
- Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27Kip1 by PKB/Akt-mediated phosphorylation in breast cancerNature Medicine, 2002
- Interaction and colocalization of PGP9.5 with JAB1 and p27Kip1Oncogene, 2002